Enhancing global access to cancer medicines

Javier Cortés(Villa Maria Hospital), Joaquı́n Arribas(Hospital Del Mar), Peter A. Kaufman(University of Vermont), Josep Tabernero(Deaconess Hospital), Fátima Cardoso(Breast Cancer Alliance), Nadia Harbeck(Breast Center), Antonio Llombart‐Cussac(MedSIR (Spain)), Nagi S. El Saghir(American University of Beirut Medical Center), Alexandru Eniu(Institute of Oncology Prof. Dr. Ion Chiricuta), Peter Schmid(St Bartholomew's Hospital), Laura García‐Estévez(MD Anderson Cancer Center Madrid), José Manuel Pérez-García(MedSIR (Spain)), Carlos H. Barrios(Eastern Cooperative Oncology Group), S. M. S. Wagle(Bridgepoint (United Kingdom)), Javier Pareja Román, Giuseppe Curigliano(European Institute of Oncology)
CA A Cancer Journal for Clinicians
February 18, 2020
10.3322/caac.21597
Cited by 205

Related Papers

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k